Get in touch

TIEFENBACHER GROUP enlarges its manufacturing facilities in India and Cyprus

Tiefenbacher Group - A collage showcases Tiefenbacher Group facilities, highlighting modern glass-fronted offices, industrial buildings, manufacturing equipment, and the Tiefenbacher Group logo, reflecting their commitment to patient-centric drug development and pharmaceutical healthcare solutions.

Driving efficiency is our key – TIEFENBACHER GROUP enlarges its manufacturing facilities in India and Cyprus for powerful drug productionDid you know that TIEFENBACHER GROUP heavily invests in its own manufacturing facilities to secure an efficient and reliable supply of our high-quality pharmaceuticals for patients around the world? As fully integrated pharmaceutical company, we offer […]

TIEFENBACHER GROUP at CPhI in Milan 2021

Tiefenbacher Group - A modern exhibition booth for TIEFENBACHER GROUP, a family-owned pharmaceutical company, features a bold blue design, illuminated logo, reception counter, and several people interacting inside a convention or trade show setting.

Reach out to the TIEFENBACHER GROUP at CPHI in Milan 2021 and discover our latest innovations to make pharmaceuticals more affordable, more available, and better than before.“Nothing can replace meeting each other in person!” says Oliver Schrader, Managing Director of Tiefenbacher Group. After nearly two years of mainly digital work, we are very excited to […]

Tiefenbacher Pharmaceuticals: Launch of first generic version of the antihistamine Bilastine

Tiefenbacher Group - A smiling woman with long hair stands in a field of yellow flowers under a clear sky. The Tiefenbacher Pharmaceuticals logo in the top left highlights their dedication to patient-centric drug development and innovative pharmaceutical healthcare solutions.

New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the antihistamine BilastineWe at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level or nationality. That´s why we are excited to share that we have successfully launched the first generic version of Bilastine (20 […]

New agreement expands collaboration between OnDosis and TIEFENBACHER GROUP

Tiefenbacher Group - Two white and teal handheld medical devices with digital displays showing “10 mg,” next to the Tiefenbacher Group and Ondosis logos, highlight advanced pharmaceutical healthcare solutions for finished dosage forms on a white background.

Innovative Healthcare Pharmaceuticals with e-health technology in the ADHD field, rare diseases, and transplantation medicineSwedish Life science company OnDosis and German B2B pharmaceutical company TIEFENBACHER GROUP initiate four new innovative development projects targeting ADHD, rare diseases, and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving […]

TIEFENBACHER GROUP supports Post COVID-19 with Posaconazole against Black Fungus (Mucormycosis)

Tiefenbacher Group - A scientist wearing safety goggles and a lab coat closely observes equipment in a laboratory focused on patient-centric drug development, surrounded by scientific instruments and glassware.

TIEFENBACHER GROUP supports Post COVID-19 with Posaconazole tablets against Black Fungus (Mucormycosis) in IndiaBlack Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised patients. However, many patients who have survived their COVID-19 infection with the help of external […]

TIEFENBACHER PHARMACEUTICALS: Launch of generic version of Teriflunomide, Multiple Sclerosis (MS)

Tiefenbacher Group - A group of five older adults, three men and two women, stand close together outdoors, smiling and laughing under leafy trees on a sunny day, reflecting the joy that patient-centric drug development brings to thriving communities in a lush park setting.

TIEFENBACHER PHARMACEUTICALS announces global generic launch of Teriflunomide – making multiple sclerosis therapy more affordable and better available worldwideTiefenbacher Pharmaceuticals has successfully developed a global dossier for a generic version of Teriflunomide 7 mg and 14 mgfilm-coated tablets. Generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. Teriflunomide […]

AET Pharma US Inc., Part of Tiefenbacher, approval of Abbreviated New Drug Application (ANDA) for Posaconazole

Tiefenbacher Group - A large group of people, including men and women in formal and colorful traditional attire, stand on a grassy lawn with a modern glass building behind them, reflecting the unity of a family-owned pharmaceutical company dedicated to patient-centric drug development.

AET Pharma US Inc. announces successful approval of Abbreviated New Drug Application (ANDA) for PosaconazoleOn 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole in 100 mg Delayed-Release Tablets. This is another milestone for TIEFENBACHER GROUP in further strengthening its product […]

Get in touch